USD 2.07
(-0.48%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 16.36 Million USD | -4.12% |
2022 | 17.06 Million USD | -43.41% |
2021 | 30.15 Million USD | 349.52% |
2020 | 6.7 Million USD | 109.36% |
2019 | 3.2 Million USD | 255.21% |
2018 | 902 Thousand USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 337.6 Million USD | 1669.13% |
2024 Q1 | 19.08 Million USD | 16.63% |
2023 FY | 16.36 Million USD | -4.12% |
2023 Q3 | 19.28 Million USD | 14.92% |
2023 Q4 | 16.36 Million USD | -15.14% |
2023 Q1 | 15.98 Million USD | -6.32% |
2023 Q2 | 16.77 Million USD | 4.95% |
2022 Q3 | 18.55 Million USD | -30.4% |
2022 Q4 | 17.06 Million USD | -8.03% |
2022 Q2 | 26.65 Million USD | -5.61% |
2022 Q1 | 28.24 Million USD | -6.34% |
2022 FY | 17.06 Million USD | -43.41% |
2021 Q2 | 25.32 Million USD | -1.5% |
2021 FY | 30.15 Million USD | 349.52% |
2021 Q4 | 30.15 Million USD | 6.08% |
2021 Q1 | 25.71 Million USD | 283.35% |
2021 Q3 | 28.42 Million USD | 12.23% |
2020 FY | 6.7 Million USD | 109.36% |
2020 Q4 | 6.7 Million USD | -9.72% |
2020 Q3 | 7.43 Million USD | 88.72% |
2020 Q2 | 3.93 Million USD | 0.0% |
2020 Q1 | - USD | -100.0% |
2019 FY | 3.2 Million USD | 255.21% |
2019 Q4 | 3.2 Million USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2018 FY | 902 Thousand USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ADC Therapeutics SA | 503.03 Million USD | 96.747% |
Alto Neuroscience, Inc. | 158.3 Million USD | 89.664% |
Annovis Bio, Inc. | 17.95 Million USD | 8.893% |
Biohaven Pharmaceutical Holding Company Ltd. | 85.23 Million USD | 80.804% |
Ginkgo Bioworks Holdings, Inc. | 568.19 Million USD | 97.12% |
Nuvation Bio Inc. | 16.36 Million USD | 0.0% |
Arcus Biosciences, Inc. | 633 Million USD | 97.415% |
Zymeworks Inc. | 116.07 Million USD | 85.904% |